Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHV-1100
- Development stage
- Unknown
- Lead developer
- Biohaven
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BHV-1100 is an investigational **antibody recruiting molecule** developed by Biohaven for **multiple myeloma**. It is described as a **synthetic bispecific therapeutic** that binds **CD38** on myeloma cells and engages endogenous **immunoglobulin** to recruit immune effector function, thereby promoting **natural killer cell-mediated antibody-dependent cellular cytotoxicity**. Biohaven has studied BHV-1100 in combination with **autologous cytokine induced memory-like natural killer cells**, immune globulin, and low-dose IL-2, particularly in the setting of patients with multiple myeloma undergoing autologous stem cell transplant. The program has been presented as a next-generation ARM platform asset and has been reported to have received orphan drug designation for multiple myeloma.
- Other names
- CD38-ARMCD-38-ARMCD 38-ARM
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on BHV-1100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHV-1100.